Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes
Aaron's Company shares soared as it announced an acquisition by fintech firm IQVentures for $10.10 per share, a 34% premium over its recent closing price, marking a significant shift to private ownership with a valuation around $504 million.
U.S. stocks are gearing up for a cautious start following last week’s record run, with the index futures currently showing mixed sentiment. Tech stocks could extend the strength but it remains to be seen if that pervades into the broader market.